Genomic Vision: Changes in the Company’s Governance
13 Julho 2022 - 1:00PM
Business Wire
Regulatory News:
GENOMIC VISION (Paris:GV) (FR0011799907 – GV – the
“Company”), a biotechnology company that develops tools and
services dedicated to the analysis and control of changes in the
genome, today announced changes in its governance following the
Company’s ordinary general meeting held on July 11, 2022 at Genomic
Vision’s headquarters.
The resolutions put forward and approved during this general
meeting included:
- the revocation of Mrs. Remy-Renou’s mandate as Chair of the
Executive Board and the appointment of a new member of the
Executive Board, Mrs. Emilie Chataignier;
- the revocation of the mandates of all the members of the
Supervisory Board – Mrs. Elisabeth Ourliac, Mrs. Tammou Abikhzer
and Mr. Stéphane Verdood – and the appointment of Mrs. Florence
Alouch, Mr. Mohammed Afshar and Mr. Eric Edery for a 6-year term as
provided for in the Company’s articles of association.
The reconstituted Supervisory Board met following the ordinary
general meeting and decided to appoint Mrs. Florence Alouch as
Chair of the Supervisory Board and Mr. Aaron Bensimon as Chair of
the Executive Board.
The objective of these changes in Genomic Vision’s governance is
to strengthen the Company’s commercial momentum.
The minutes of the ordinary general meeting of July 11, 2022
will be made available in the Investors / General Assembly section
of the Company’s website within the statutory timeframe.
***
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Genomic Vision, based near Paris in Bagneux, is a
public listed company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
***
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 14, 2022 under
reference number R.22-0293, as updated by the amendment filed with
the AMF on May 20, 2022, under number D.22-0293-A01, available on
the web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220713005627/en/
Genomic Vision Aaron Bensimon CEO Tel.: +33 1 49 08 07 51
investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
Tel.: +33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Goldfield (AMEX:GV)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Goldfield (AMEX:GV)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024